Pharmaceutical company focusing to cancer and neurology drugs.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two
global business groups: oncology and neurology (dementia-related
diseases and neurodegenerative diseases). Each group functions as an
end-to-end global business with discovery, development, and marketing
capabilities. Our U.S. headquarters, commercial and clinical development
organizations are located in New Jersey; our discovery labs are in
Massachusetts and Pennsylvania; and our global demand chain organization
resides in Maryland and North Carolina.
Visit website: https://www.eisai.com/index.html
Eisai's Lecanemab drug proves to slowdown Alzheimer's disease, unlike aducanumab drug
BBC - 28-Sep-2022
Historic moment for dementia research-large clinical trial to successfully slow cognitive declineRead more...
Biogen's Alzheimer's drug trials halted
CNN - 21-Mar-2019
Another promising candidate not making it to the finish lineRead more...